RxDoctor Payments Data

David Newsome, MD

Family Medicine · Metairie, LANPI 1932634813

Payments from drug & device makers

$3,788in general payments, 2019–2025

Across 197 payments — averaging $19.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$856
  • AstraZeneca$600
  • Astellas Pharma US Inc$242
  • Pfizer$216
  • Novo Nordisk$205
  • Lilly USA, LLC$202
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$3,67497%
  • Education$1143%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,788 in reported general payments places this provider in the 75th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$95,725
Medicare patients
261
Services billed
1,033

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide104$180,505
EliquisApixaban92$106,690
JardianceEmpagliflozin53$79,220
Nurtec OdtRimegepant Sulfate27$50,019
Trelegy ElliptaFluticasone/Umeclidin/Vilanter52$45,035
TrulicityDulaglutide19$41,495
JanuviaSitagliptin Phosphate30$38,387
MounjaroTirzepatide34$38,068
MyrbetriqMirabegron33$31,867
FarxigaDapagliflozin Propanediol26$29,824
XareltoRivaroxaban29$27,422
GemtesaVibegron22$19,506
Tresiba Flextouch U-200Insulin Degludec14$15,182
EntrestoSacubitril/Valsartan14$15,120
LinzessLinaclotide15$12,599

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$205$180,505104 claims
PfizerEliquis, Nurtec Odt$216$156,710119 claims
Lilly USA, LLCTrulicity, Mounjaro$202$79,56453 claims
Boehringer IngelheimJardiance$159$79,22053 claims
GSKTrelegy Ellipta, Breo Ellipta$200$53,12270 claims
MerckJanuvia$134$38,38730 claims
AstraZenecaFarxiga, Symbicort$600$38,15255 claims
Astellas Pharma US IncMyrbetriq$242$31,86733 claims
Johnson & JohnsonXarelto$79$27,42229 claims
Sumitomo Pharma America, Inc.Gemtesa$132$19,50622 claims
AbbVieLinzess, Synthroid$856$17,35855 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Metairie

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →